50,760 Shares in Hologic, Inc. (NASDAQ:HOLX) Bought by Jensen Investment Management Inc.

Jensen Investment Management Inc. purchased a new position in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 50,760 shares of the medical equipment provider’s stock, valued at approximately $3,659,000.

Other large investors also recently bought and sold shares of the company. Swedbank AB increased its position in Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after acquiring an additional 306,562 shares during the last quarter. GSA Capital Partners LLP increased its position in Hologic by 22.2% during the third quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider’s stock valued at $469,000 after acquiring an additional 1,048 shares during the last quarter. KBC Group NV increased its position in Hologic by 2.1% during the third quarter. KBC Group NV now owns 87,629 shares of the medical equipment provider’s stock valued at $7,138,000 after acquiring an additional 1,820 shares during the last quarter. Metis Global Partners LLC increased its position in Hologic by 4.1% during the third quarter. Metis Global Partners LLC now owns 15,655 shares of the medical equipment provider’s stock valued at $1,275,000 after acquiring an additional 623 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. increased its position in Hologic by 14.2% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 6,007 shares of the medical equipment provider’s stock valued at $489,000 after acquiring an additional 748 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Stephens reissued an “overweight” rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, Citigroup lowered their target price on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Stock Up 0.0 %

NASDAQ:HOLX opened at $60.71 on Monday. The firm has a market cap of $13.62 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a 50-day moving average of $67.18 and a 200 day moving average of $74.64. Hologic, Inc. has a 1-year low of $60.33 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.